drugset / Trial / NCT06577090

Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

NCT06577090

Phase 2 Active not recruiting 136 enrolled Skye Bioscience, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a proof-of-concept study to assess the safety and efficacy of Nimacimab Injection compared to an active and placebo injection control.

Timeline

Start
2024-08-22
Primary completion
2026-11-20
Completion
2027-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Nimacimab Monoclonal antibody 200 mg
Subject Nimacimab Monoclonal antibody 300 mg
Background Semaglutide Peptide 2.4 mg

Indications